Scientists identify pan-cancer biomarkers
Genomics and transcriptomics have successfully identified many therapeutic targets for cancer. However, changes in protein abundances and their chemical modifications can also drive tumor progression. To consider this additional dimension, Guo-sheng Hu, Zao-zao Zheng, Yao-hui He, Du-chuang Wang and colleagues at Xiamen University analyzed RNA and protein data from thousands of patients with 13 cancer types. They published their findings in Molecular & Cellular Proteomics. Using bioinformatics tools, they identified upregulated and downregulated genes specific to each cancer type as well as genes common to most types analyzed.

The team discovered that tissue-specific genes were downregulated at both RNA and protein levels in all cancer types, indicating a loss of tissue identity. They showed that many genes involved in messenger RNA splicing, interferon pathway, fatty acid metabolism, and complement coagulation cascade, were dysregulated across several cancer types. The authors also found that ADH1B, the alcohol dehydrogenase that converts ethanol to acetaldehyde, was significantly downregulated in all cancer types. Conversely, the ribonucleotide regulatory subunit RRM2 was overexpressed. These proteins are examples of potential pan-cancer biomarkers, which can be used to discern cancer tissues from normal cells and potentially inform novel therapeutic strategies.
Effective cancer treatment also requires knowledge of the tumor’s stage of progression. To identify biomarkers for each tumor stage, the team analyzed how the cancer proteome changed throughout tumor progression. They used these findings to build models for tumor stage classification of several cancer types based on these biomarkers. They further constructed prognostic risk stratification models for corresponding cancer types based on dysregulated genes. They found that these models, when combined with the tumor-node-metastasis classification system, predicted cancer patient prognosis more accurately than either approach individually.
Protein-based approaches like these could be the key to better understanding cancer mechanisms and developing better treatments. Inhibitor drugs targeting RRM2 and other differentially expressed proteins identified in this study could be used to treat a range of cancer types and will be investigated further in future studies.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Innovative platform empowers scientists to transform venoms into therapeutics
Scientists combine phage display and a “metavenome” library to discover new drugs that bind clinically relevant human cell receptors. Read about this recent Molecular & Cellular Proteomics paper.

Meet Shannon Reilly
The JLR junior associate editor discusses the role of adipocytes in obesity at Weill Cornell Medical School.

Meet Donita Brady
Donita Brady is an associate professor of cancer biology and an associate editor of the Journal of Biological Chemistry, who studies metalloallostery in cancer.

Glyco get-together exploring health and disease
Meet the co-chairs of the 2025 ASBMB meeting on O-GlcNAcylation to be held July 10–13, 2025, in Durham, North Carolina. Learn about the latest in the field and meet families affected by diseases associated with this pathway.

Targeting toxins to treat whooping cough
Scientists find that liver protein inhibits of pertussis toxin, offering a potential new treatment for bacterial respiratory disease. Read more about this recent study from the Journal of Biological Chemistry.

Elusive zebrafish enzyme in lipid secretion
Scientists discover that triacylglycerol synthesis enzyme drives lipoproteins secretion rather than lipid droplet storage. Read more about this recent study from the Journal of Biological Chemistry.